The US Food and Drug Administration (FDA) has approved Blue Earth Diagnostics’ prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent, POSLUMA (flotufolastat F 18). The high-affinity radiohybrid is the first and only FDA-approved agent of its kind. It will be widely accessible for patients across the United States. ...
Advertisement
Advertisement
Latest News
Dr. Dorff explains how the prognostic model from the CALGB 90401 trial provides accurate information to patients with mCRPC.
Tumor grade, sarcomatoid features may influence outcomes with adjuvant nivo/ipi in patients with RCC after nephrectomy.
EV plus pembrolizumab continues to demonstrate promising survival trends with durable responses in first-line la/mUC.
The prevalence, outcomes of patients with HRR mutations who initiated 1L mCRPC treatment with a novel hormonal therapy.
The postsurgical treatment of functional outcomes such as UI and ED after SRP remains a challenge for all urologists.
FDA approval of Adstiladrin for use in BCG-unresponsive nMIBC expands the armamentarium for treatment of high-risk nMIBC.
The recent AUA/SUO guideline on the management of non-metastatic UTUC includes 2 recommendations for lymph node dissection.
Dr. Siefker-Radtke shares the novel targeted therapies for bladder cancer and how they are assessed in combinations.
PSA nadir ≥0.1 ng/mL within 6 months of RT completion may be prognostic for long-term outcomes in patients receiving ...
A prospective study shows activity after treatment intensification with a triplet combination regimen in patients with RCCvh.
The largest analysis of outcomes for patients with sarcomatoid or rhabdoid metastatic nccRCC treated with IO-based regimens.
Post hoc analyses from JAVELN Bladder 100 shed light on the long-term safety profile of avelumab first-line maintenance.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, MScEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
David Ambinder, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
Expert Interviews
Dr. Siefker-Radtke shares the novel targeted therapies for bladder cancer and how they are assessed in combinations.
Dr. Msaouel shares his journey to becoming a world expert in RMC and the clinical trial work he led to improve outcomes.
Katherine Virgo, PhD, MBA, provided insight into ASCO's updated guideline for the management of metastatic prostate cancer.
Michigan Urological Surgery and Improvement Collaborative is an effort to improve patient lives through high-quality care.
A recent study examined safety and efficacy from the ARASENS trial for certain subgroups by disease volume and risk.
Dr. A. Ari Hakimi discusses how cytoreductive nephrectomy has evolved and is being used in today’s mRCC treatment paradigm.
Knowledge Hubs
Curated clinical content based on conditions, therapies, and technologies
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get research and breaking news straight to your inbox.
The Uromigos
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Conference Coverage
Live meeting highlights
Tumor grade, sarcomatoid features may influence outcomes with adjuvant nivo/ipi in patients with RCC after nephrectomy.
EV plus pembrolizumab continues to demonstrate promising survival trends with durable responses in first-line la/mUC.
The prevalence, outcomes of patients with HRR mutations who initiated 1L mCRPC treatment with a novel hormonal therapy.
PSA nadir ≥0.1 ng/mL within 6 months of RT completion may be prognostic for long-term outcomes in patients receiving ...
Video Insights
Clinical discussions with experts in the field
